Axsome Therapeutics (AXSM) to Release Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, February 18th. Analysts expect Axsome Therapeutics to post earnings of ($0.97) per share and revenue of $118.09 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period in the prior year, the firm posted ($1.32) EPS. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Axsome Therapeutics Trading Down 0.4 %

Shares of NASDAQ:AXSM traded down $0.53 during trading on Friday, reaching $131.15. The stock had a trading volume of 1,064,118 shares, compared to its average volume of 1,095,030. The firm's fifty day moving average is $97.84 and its 200 day moving average is $93.27. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $134.18. The stock has a market cap of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05.

Remove Ads

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $190.00 target price on shares of Axsome Therapeutics in a research report on Tuesday. Needham & Company LLC reiterated a "buy" rating and set a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday. Royal Bank of Canada reiterated an "outperform" rating and set a $139.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. StockNews.com upgraded shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Bank of America upped their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a report on Tuesday. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $147.13.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.